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Abstract
Purpose TNF-α induces fractalkine (CX3CL1) and its recep-
tor CX3CR1 in endothelial cells through NF- B activation.
NF- B inhibitors may reduce the expression of CX3CL1,
and modulation of the CX3CL1/CX3CR1 signaling was pro-
posed as a new target for aspirin. We examined the effects of
aspirin on CX3CL1 and TNF-α production, as well as
CX3CR1 and TNFR1 expression.
Methods HUVECs isolated after term pregnancies (N=28)
were cultured in vitro. Lipopolysaccharide (1μg/ml) was used
as CX3CL1 inducer. HUVECs were exposed to six different
concentrations of aspirin (between 1.0 and 6.0 mM) during
7 days. The levels of CX3CL1 and TNF-α in the culture
media were measured using ELISA. After termination of the
cultures, mean expressions of CX3CR1 and TNFR1 were ex-
amined in the immunostained paraffin sections using quanti-
tative immunohistochemistry.
Results Aspirin significantly (p<0.05) decreased CX3CL1
production, and the mean decrease in CX3CL1 production
was inversely proportional to increased (p<0.05) expression
of CX3CR1. The combined mean CX3CL1 concentrations,
including all time points, equaled 782.18±74.4 pg/ml in
aspirin treated HUVECs compared to a total concentration
of 2467.53±127.5 pg/ml combined from the respective time
points in the controls.
An inhibition of TNF-α production in HUVECs after pre-
treatment with aspirin was observed. Unlike in the case of
CX3CR1 expression, there were no signs of TNFR1
upregulation.
Conclusions Autoregulation between CX3CL1 and CX3CR1
may explain overexpression of CX3CR1 as the compensatory
effect in aspirin-treated HUVECs. Inhibition of CX3CR1
could prevent thrombotic complications in the early period
after discontinuation of aspirin.
Keywords Aspirin . Endothelial cells . Fractalkine .
CX3CR1 . TNF-α . TNFR1
Introduction
In 1897, the German chemist Felix Hoffmann was working
for Friedrich Bayer and Company and synthesized
acetylsalicylic acid (ASA) for the first time in a stable form
that was usable for medical applications. In 1899, this com-
pound was launched under the trade name Aspirin by Bayer
Company [1]. After many years, aspirin is still one of the most
widely used medications worldwide because of its anti-
clotting, analgesic, anti-pyretic, and anti-inflammatory prop-
erties. The results of many studies provided detailed disclo-
sure of the main mechanisms of aspirin’s action, indicating
potential benefits towards the preventive treatment of heart
attacks and strokes [2–4]. Aspirin produces irreversible inac-
tivation of cyclooxygenase (COX), an enzyme required for
the conversion of arachidonic acid into important mediators
known as prostanoids, including thromboxanes, prostacyclin
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and other prostaglandins. With regard to this property, aspirin
differs from most other non-steroidal anti-inflammatory drugs
(NSAIDs), which are reversible inhibitors [3]. Aspirin-related
inhibition of COX is a consequence of the acetylation of a
specific serine moiety (serine 530 and serine 516 of the
COX-1 and COX-2 isoforms, respectively) [5]. Although it
is a non-selective COX inhibitor, aspirin given in lower doses
is approximately 170-fold more potent in inhibiting COX-1
than COX-2 [5]. Other effects of aspirin have also been re-
ported, such as the uncoupling of oxidative phosphorylation in
mitochondria and an influence on nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) dependent intra-
cellular signaling pathways [6]. This latter effect of aspirin,
influencing a local endothelial-related cytokine network, may
be linked to delayed progression of atherosclerosis [7, 8].
The chemokine CX3CL1 (fractalkine, neurotactin) is
unique in that it exhibits properties of both a chemoattractant
(the soluble form of the protein) and an adhesive compound
(the cell membrane-anchored form); therefore, CX3CL1 is an
important player in the pathogenesis of different inflammatory
diseases, including atherosclerotic plaque formation [9]. To
date, encoded on human chromosome 16 and possessing three
amino-acid residues located between the first two cysteine
residues in the molecule, CX3CL1 is the lone member of the
CX3C (delta) subfamily of chemokines [10]. The biological
activities of CX3CL1 are mediated by its sole receptor
CX3CR1 (previously denoted as V28), a Gαi protein-linked
seven-transmembrane receptor [11]. CX3CR1 is expressed in
endothelial cells, mast cells, monocytes, natural killer (NK)
cells, microglial cells, neurons, and subpopulations of T-
lymphocytes [12]. Following CX3CR1 stimulation, activation
of both CX3CL1-dependent and integrin-dependentmigration
of cells with augmented adhesion in result of synergistic reac-
tions should be expected. CX3CL1 shows potent
chemoattractant properties for NK cells, T cells and mono-
cytes, but not neutrophils. Moreover, CX3CL1 exerts cytotox-
ic effects on endothelial cells [13]. Endothelial cells express
substantial levels of CX3CL1, and considering additional syn-
ergistic effects of TNF-α and IFN-γ, almost every stimulus
influencing cell homeostasis may induce CX3CL1 secretion
[14, 15].
Inhibition of the CX3CL1/CX3CR1 signaling pathway
ameliorated the severity of atherosclerosis in animal models
[16]. Epidemiological human studies revealed that decreased
activity of the CX3CL1/CX3CR1 pathway due to genetic fac-
tors may be associated with a lower risk of atherosclerosis as
well as a decreased incidence in the episodes of plaque desta-
bilization [17]. CX3CL1 may induce its own expression via
the PI3-kinase/PDK1/Akt/NIK/IKK/ nuclear factor kappa be-
ta (NF- B) signaling pathway [18].
TNF-α also induces the expression of fractalkine and
CX3CR1 in the vascular cells, and this induction is mediated
by NF- B activation [19]. The protein encoded in humans by
the TNFRSF1A gene is one of the major receptors for TNF-α,
and TNFR1(CD120a) can be detected in almost all cell types,
including endothelial cells. This receptor can activate the tran-
scription of NF- B, modulates the inflammatory response and
mediates apoptosis [20].
Having proved that specific NF- B inhibitors markedly re-
duces the expression of CX3CL1, modulation of the
CX3CL1/CX3CR1 signaling pathway was recently proposed
as a new target for aspirin [21, 22].
The aim of this preliminary study was to examine the ef-
fects of different doses of aspirin on CX3CL1 and TNF-α
production, as well as CX3CR1 and TNFR1 expression in
human umbilical vein endothelial cells (HUVECs).
Material and Methods
The study was conducted in compliance with international and
local laws regarding human experimentation and was official-
ly approved by the local ethics committee. Written consent
was obtained from the women for use of their extraplacental
membranes. This study was carried out in accordance with
The Code of Ethics of the World Medical Association (Dec-
laration of Helsinki) for experiments involving humans, and
the Uniform Requirements for manuscripts submitted to Bio-
medical Journals have been fulfilled.
HUVECs were isolated from umbilical cords (N=28) ob-
tained from uncomplicated single pregnancies delivered at
term by elective cesarean sections. The indications for cesar-
ean section were: high grade myopia in the pregnant woman
and breech presentation of the fetus. A more detailed clinical
characteristic of the two homogenous groups are given in
Table 1. Within a maximum period of 10 min following de-
livery, fresh umbilical cords were cut off from each placenta
with approximately the same length of 15 cm. The outer sur-
face of the cord was cleaned with PBS (Gibco®), and after
gently filling the umbilical vein with PBS containing
antibiotic/antimycotic (penicillin, streptomycin, and
amphotericine B), the cord was clamped on both ends and
transported on ice for a short period (approx. 30 min) before
HUVEC isolation.
Cell Culture & Determination of CX3CL1 Levels
The method of HUVEC isolation was similar to the procedure
described by Crampton et al. [23]. Collagenase treatment was
performed, and isolated cells were cultured on plates coated
with gelatin. Briefly, fresh, precise cuts on both ends of the
cord were performed, and a 21 1/2 G needle with a plastic
needle sheath was inserted into the lumen of the vein and then
clamped into place with a hemostat. Hank’s balanced salt so-
lution (HBSS; Gibco® Inc., Grand Island, NewYork, USA) in
a 20 cc syringe was attached to the needle, and the vein was
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flushed twice to eliminate blood residues and the PBS. Next,
the 20 cc syringe was disconnected, and a 10 cc syringe was
attached to push 10 ml of 0.1 % collagenase into the umbilical
vein. After the short flushing phase, the open end of the cord
was clamped, and the vein was filled with collagenase until
moderate distention occurred. The incubation phase in Ca/Mg
free Dulbecco’s phosphate-buffered saline (DPBS; Gibco®) at
37 °C for 20min was accompanied by gentlymassaging of the
cord. After incubation, all effluent was collected in a conical
tube containing fetal bovine serum (FBS) and centrifuged for
5 min at 1,200 grm at room temperature. The supernatant was
aspirated, and the cell pellets were resuspended in standard
CS-C medium (Sigma, St. Louis, MO, USA) supplemented
with endothelial cell growth factor and endothelial cell attach-
ment factor. HUVECs were seeded at a density of 1×105 cells/
well in gelatinized 24-well culture plate inserts. A total of 56
plates were seeded (2 plates per 1 umbilical cord) with
HUVECs. The yield and viability of the isolated HUVECs
were assessed by the Trypan blue exclusion assay. Twenty-
four hours after plating, lipopolysaccharide (LPS, 1 μg/ml)
was added to the culture media to induce secretion of
CX3CL1. Then, the HUVECs were continuously exposed to
aspirin (Sigma) administered in 6 different concentrations
(1.0, 2.0, 3.0, 4.0, 5.0, and 6.0 mM) in respective groups
(designated as groups I to VI, and the control, aspirin free
group was designated as group VII) during the 7 day culture
period in normoxia at 37 °C. A colorimetric assay utilizing
3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bro-
mide (MTT; Sigma) was used to assess HUVEC viability
before and after exposure to the given doses of aspirin (the
time points 24, 48, 72, and 144 h.
The levels of CX3CL1 in the culture media supernatants
were measured at 24, 48, 72, and 144 h time points using a
RayBio® Human Fractalkine ELISA Kit (RayBiotech, Inc.,
USA). According to the manufacturer’s information, the min-
imum detectable dose of CX3CL1 for this test is typically less
than 300 pg/ml, and cross reactivity was not observed with
any of the cytokines tested including human angiogenin,
BDNF, BLC, ENA-78, FGF-4, IL-1α, IL-1β, IL-2, IL-3, IL-
4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 p70, IL-12 p40,
IL-13, IL-15, IL-309, IP-10, G-CSF, GM-CSF, IFN-γ, leptin,
MCP-1, MCP-2, MCP-3, MDC, MIP-1α, MIP-1β, MIP-1δ,
PARC, PDGF, RANTES, SCF, TARC, TGF-β, TIMP-1,
TIMP-2, TNF-α, TNF-β, TPO, and VEGF.
Determination of the TNF-αConcentration in the Culture
Media
Additionally, measurements of the TNF-α level in the culture
supernatants were performed among all studied HUVEC
groups by ELISA with the same timing adopted for the
CX3CL1 concentration assessment. A commercially available
kit was used (ELH-TNFalpha-001, RayBio Human TNF-
alpha ELISA Kit, RayBiotech, Inc., USA) according to the
manufacturer’s instructions. As assured by the producer, the
minimum detectable dose of TNF-α was typically less than
10 pg/ml.
Immunohistochemistry and Mean Expression of CX3CR1
To visualize CX3CR1 by immunohistochemistry, the cultures
were terminated, formalin fixed and paraffin embedded. Both
Table 1 Clinical characteristics
of the two groups studied. The
donors of the umbilical cords (N=
28) were pregnant women after
uncomplicated single pregnancies
terminated by elective cesarean
section at term
Age of the mothers in full years (range; mean; median) 24–30; 27; 27
Parity (nulliparous/primiparous mothers) 17/11
Gestational age in days pregnancy 270–282; 277; 275
Blood pressure during pregnancy All records within normal rangea
Proteinuria during pregnancy Not present
Liver blood tests (aminotransferases enzymes, AST and ALT levels) Within normal rangeb
Smoking during pregnancy None declared active smoking
Diabetes during pregnancy Not present
Body mass index <21 or >35 None
Mother’s blood (III trimester): hematocrit (Ht), hemoglobin (Hb), red
blood cell (RBC) count, mean cell hemoglobin concentration (MCHC)
All within normal rangec
Other identified risk factors None
Birth weight in grams (range; mean; median) 3,050–3,980; 3,570; 3400
Sex of newborns (M—male; F—female) 15M+13 F
Weight of placenta in grams (range; mean; median) 552–825; 655; 649
a The normal range of blood pressure was define as systolic pressure between 100 and 140 mmHg, and diastolic
pressure between 60 and 90 mmHg
b The normal range of values for AST is 5–40 units per liter of serum and the normal range of values for ALT is 7–
56 units per liter of serum
cHb levels 10.0–13.5 g/dl; RBC count 3.2–4.4 million/μl; MCHC 319–355 g/L; Ht 31–41 %
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initial (Ei; after LPS exposure but not exposed to aspirin) and
final (Ef; after 7 days of culture) expressions of the fractalkine
receptor CX3CR1 were compared within and between studied
groups. Standard immunohistochemical procedures were ap-
plied. Rabbit polyclonal antibody IgG to CX3CR1 (ab8020;
Abcam Inc., USA; concentration of 10 μg/ml) was used as the
primary antibody and a goat anti-rabbit IgG biotinylated anti-
body was used as the secondary antibody (ab64256; Abcam;
0.5 % v/v). Visual detection of the primary anti-receptor anti-
bodies was performed using the StreptABComplex/HRPDuet
(Dako Cytomation, Glostrup, Denmark) following the proce-
dure recommended by the manufacturer, with 3,3′-diamino-
benzidine serving as a chromogen. The negative controls for
immunostainings were set up by replacement of the polyclon-
al primary antibody with normal rabbit pre-immune IgG di-
luted with phosphate buffered saline containing 3 % bovine
serum albumin at the same protein concentration as that used
for the primary antibody.
Thereafter, quantitative immunohistochemistry based on
morphometric software (Quantimet 500C+, Leica, UK) was
applied for CX3CR1 receptor identification in paraffin-
embedded 5 μm sections of the HUVECs cultures under light
microscopy. For comparison and validation, all these morpho-
metric operations were carried out twice by two independent
observers, and the average results were recorded. The intensi-
ty of immunostaining was evaluated using a mean color satu-
ration parameter and thresholds in grey-level histograms. The
expression of CX3CR1 corresponded to the total immuno-
stained calibrated area of examined sections, whereas color
saturation comprised segmentation-separation criteria for ob-
jects. A single analyzed image area was 138,692 μm2 (mag-
nification x 200). For each umbilical cord collected as a source
of the HUVECs culture, twelve visual fields were analyzed. In
all studied groups, 336 visual fields were analyzed (168 visual
fields per each time point marked Ei and Ef as previously
stated). Thus, 24 visual fields were analyzed within each
group I-VII (12 at time point Ei and 12 at Ef). To assure
optimal accuracy of measurements, the following factors have
been controlled for or monitored: illumination, power supply,
warming up, shading correction, averaging of image intake,
hue, luminance, and relation of illumination to quantification
of area percentage of positively staining structures. A more
detailed description of these morphometric procedures is giv-
en elsewhere [24, 25]. Morphometric results comprising 90 %
confidence intervals were reported as the mean percentage
values±SEM.
Immunohistochemistry and Mean Expression of TNF-α
Receptor Type 1 (TNFR1)
To identify the TNF-α receptor type 1 (TNFR1, TNFRSF1A,
CD120a), an immunohistochemical staining procedure was
utilized with a goat anti-human polyclonal antibody IgG to
TNF R1/TNFRSF1A (AF225; R&D Systems, Inc., USA;
concentration of 10 μg/ml) as the primary antibody, and an
Anti-Goat HRP-AEC Cell & Tissue Staining Kit (CTS009;
R&D) was used to obtain formation of the Avidin-Biotin
Complex (ABC) followed by visualization based on enzymat-
ic conversion of a chromogenic substrate 3-amino-9-
ethylcarbazole (AEC) into colored red precipitate by horse-
radish peroxidase (HRP) at the sites of antigen localization.
Identification of HUVECs immunostained for TNFR1 in
paraffin-embedded 5 μm sections using quantitative immuno-
histochemistry was performed in an identical manner as de-
scribed for CX3CR1, which means that both initial (Ei; after
LPS exposure but not exposed to aspirin) and final (Ef; after
7 days of culture) expressions of TNFR1 were compared.
Detection and Quantification of NF- B in the HUVECs
Lysates
To investigate comparatively the influence of different doses
of aspirin on NF- B signaling, the sandwich ELISA assay
method was applied. Following the cultures’ termination at
Day 7, the cell lysates were prepared for detection and quan-
tification of the level of NF- B/p65 protein using 96-well
plates and a microplate reader. In each of the groups, the cell
lysates were prepared from an equal number of HUVECs (1×
104 cells/100 μl) by addition of ice-cold phosphoprotein lysis
buffer (30 μl for each well) containing 4 mM sodium pyro-
phosphate, 50 mM HEPES, 100 mM NaCl, 10 mM EDTA,
10 mM NaF, 2 mM NaVO4 with 1 mM PMSF, 10 % Triton
X-100, 5 μg/ml leupeptin and 5 μg/ml aprotinin. The
Invitrogen NF- B/p65 [total] ELISA Kit [KHO0371;
Novex®] was used, and the level of NF- B/p65 protein was
assessed independent of its phosphorylation state. The analyt-
ical sensitivity of this assay was <50 pg/ml for NF- B/p65.
The p50 (NF- B1)/p65 (RelA) heterodimer assessed by
the mentioned ELISA test is the most abundant form of
NF- B [26].
Statistical Analysis
The results were expressed as the mean±SEM or mean per-
centage value±SEM and were compared by analysis of vari-
ance. Post-hoc Student’s t-tests or post-hoc Mann-Whitney’s
U-test were applied. Differences in the mean concentration of
CX3CL1, TNF-α and NF- B among groups I to VII as well as
the differences between CX3CR1 expression were deemed
statistically significant if p<0.05.
Results
Aspirin treatment produced a significant (p<0.05) decrease in
the mean concentration of CX3CL1 in the HUVECs culture
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supernatant, especially when administered at doses of 2.0 and
3.0 mM (Fig. 1, Tables 2 and 3). This curtailment of CX3CL1
production persisted throughout the whole period of observa-
tion (time points 24, 48, 72, and 144 h). The combined mean
CX3CL1 concentration for group II and group III, including
all time points, equaled 782.18±74.4 pg/ml compared to a
total concentration of 2467.53±127.5 pg/ml combined from
the respective time points in group VII (control). Analysis of
the cell viability in the HUVEC cultures revealed that the
highest tested dose of aspirin (6.0 mM) resulted in a signifi-
cant increase in cytotoxicity (Fig. 2). This effect was observed
at the beginning (24 h after aspirin administration), and the
mean cell viability still lingered below the mean values ob-
tained in the controls (p<0.05) at the respective time points.
The overall quality of CX3CR1 immunostaining in cul-
tured HUVECs was sufficient for the application of standard-
ized quantitative immunohistochemistry to investigate expres-
sion of this receptor (Fig. 3a). The mean decrease in CX3CL1
production was inversely proportional to the significantly in-
creased (p<0.05) mean final expression (Ef) of CX3CR1 (%
of the initial expression [Ei], ± SEM) in HUVECs for aspirin
concentrations 1.0, 2.0, 3.0, and 4.0 mM, amounting to
159.71±37.7, 237.98±40.4, 288.6±51.3, and 282.9±
47.6 pg/ml, respectively (Fig. 3b). The change between the
final and the initial CX3CR1 expression was not significant in
the control group (group VII).
The relationships between aspirin dose and the mean
TNF-α level in the culture media are shown in Fig. 4. A
significant inhibition of TNF-α production in HUVECs after
pretreatment with aspirin was observed throughout the whole
period of observation (time points 24, 48, 72, and 144 h) for
doses 3.0, 4.0, 5.0, and 6.0 mM. As in the case of CX3CL1,
analysis of the cell viability (Fig. 2) should raise suspicion that
the results for the highest doses of aspirin are influenced by
increased cytotoxicity in the cultured HUVECs. The mean
TNF-α level assessed together for groups III, IV, and V, com-
prising all time points, equaled 271.1±58.8 compared to
1015.75±108.3 pg/ml summed together from the same time
points in group VII (control).
The methodological correctness of the immunostaining
procedure was confirmed, and visualization of the TNFR1
was adequate for its expression assessment using quantitative
immunohistochemistry (Fig. 5a). Unlike in the case of
CX3CR1 expression, there were no signs indicating upregu-
lation of TNFR1. The mean expression of the receptor after
7 days of culture (Ef) did not significantly differ from the
starting point before aspirin treatment (Ei) but were signifi-
cantly lower (p<0.05) in groups Vand VI (Fig. 5b). However,
the results in the two latter groups may reflect augmented
cytotoxicity due to higher doses of aspirin (5.0 and 6.0 mM,
respectively). Nonetheless, despite the aspirin-related de-
creased production of TNF-α in cultured HUVECs, the mean
expression of its main receptor TNFR1(TNFRSF1A)
remained unchanged or was slightly (p>0.05) reduced (which
should be interpreted with caution, considering cytotoxicity)
compared to the initial values (Ei) obtained without pretreat-
ment with aspirin. The difference between the final and initial
expression of CX3CR1 in the control (aspirin-free) group VII
did not reach statistical significance (p>0.05).
The levels of NF- B/p65 reflected augmented production of
these proteins in HUVECs under the influence of LPS, a
known NF- B inducer, administered initially (24 h after the
cells were plated). Examination of the HUVEC cell lysates
revealed a negative correlation between the administered dose
of aspirin and the NF- B/p65 protein level (Fig. 6). In groups
III, IV, V, and VI (aspirin doses 3.0, 4.0, 5.0, and 6.0 mM,
respectively), NF- B (NF- B/p65 protein heterodimer) con-
centrations were significantly (p<0.05) lower (approximately
2-fold to 3.4-fold) compared to the control group.
Discussion
Altered endothelial function due tomicroinjury or altered met-
abolic activity may produce leukocyte adhesion and leukocyte
transendothelial migration (diapedesis), which takes part in
the pathomechanism of atheroscelerotic plaque formation
[27]. Among many other players, cytokine TNF-α and che-
mokine CX3CL1, with unique biochemical properties, are
undoubtedly involved in the destructive process that leads to
an increased propensity for coagulation and thrombosis within
the endothelial barrier [16]. Significant changes in the activity
of the genes that code for TNF-α and CX3CL1 have been
reported at the site of atherosclerosis [8, 13]. This study re-
vealed that aspirin administered within the therapeutic dose
range produces a dose-dependent reduction in the level of
both proinflammatory compounds in cultured HUVECs under
normoxia. According to the observed inhibition of NF-κB
production, this effect is mediated through a COX-
independent pathway as described by others [28, 29].
As reported in this study, the substantive differences be-
tween TNFRSF1A and CX3CR1 expressions are clearly vis-
ible and deserve in-depth discussion of the mechanisms in-
volved, including the nature of interactions between TNF-α
and CX3CL1 under conditions of NF-κB inhibition. In other
words, more studies are needed to explain why aspirin treat-
ment upregulates CX3CR1 in HUVECs while leaving TNFR
SF1A expression unchanged.
Some authors emphasized the importance of an autocrine
effect of CX3CL1-induced CX3CR1 expression on the basis
of their studies performed in aortic smooth muscle cells and
neurons [18, 30]. Because HUVECs, like most other endothe-
lial cells, express CX3CL1 and CX3CR1, existence of the
analogy is justified [31]. Such co-expression may produce
an acute induction of CX3CL1 by a wide range of proinflam-
matory factors, including TNF-α, LPS and hyperlipidemia,
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Fig. 1 Relationships between aspirin dose and the mean CX3CL1 levels in the culture media at the consecutive time points
Table 2 CX3CLI levels (pg/ml) in the HUVECs cultures measured ath the consecutive time points
Time point Group (aspirin dose [mM]
I (1.0) II (2.0) III (3.0) IV (4.0) V (5.0) VI (6.0) VII (0.0; control)
Time after induction by LPS
24 h
Mean 1670.3±166 880.8±97 984.4±78 1302.5±141 1247.3±103 1036.6±79 2352.7±140
Median 1692 819 801 1234 1266 890 2401
Range 1020–2004 473–1354 422–1251 719–1603 705–1394 368–1310 1872–3335
48 h
Mean 1498.1±111 741.0±89 678.7±40 1504.2±104 1312.5±92 1036.6±79 2833.9±105
Median 1524 762 670 1544 1272 1141 2912
Range 913–1743 407–1175 379–1075 772–1893 665–1733 368–1362 2210–3608
72 h
Mean 1352.6±107 813.8±47 754.5±104 942.3±102 1470.3±151 812.8±99 2469.1±156
Median 1295 773 701 959 1358 639 2370
Range 614–1752 481–1175 493–1032 518–1687 576–1769 330–1070 1903–2952
144 h
Mean 1058.3±98 652.8±69 751.4±71 1099.8±110 752.3±112 372.6±160 2214.4±109
Median 1008 680 713 982 844 404 2115
Range 450–1491 414–960 428–973 350–1191 409–1303 305–487 1720–2641
Mean±SEM, median (rounded to the nearest whole number), and 95 % confidence interval (95 % CI) are shown
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and may lead to vascular injury and atherosclerosis [16,
31–33]. For example, the results pertaining to murine and
human platelets in hyperlipidemic environment suggest a sig-
nificant role of the CX3CL1/CX3CR1 signaling in platelet
accumulation and monocyte recruitment at sites of arterial
damage [33].
The proinflammatory, pleiotropic, and homotrimeric solu-
ble cytokine TNF-α is implicated in somemetabolic disorders
with an inflammatory background including, but not limited
to, atherosclerosis [34]. TNF-α leads to the activation of
caspases and the two transcription factors activation protein-
1 (AP-1) and NF-κB. Acting through its type 1 receptor
TNFR1(TNFRSF1A), TNF-α typically initiates transcription-
al responses through the rapid activation of NF-κB (within
10–15 min) and/or AP-1 (within 15–30 min) [35]. Co-
stimulation of cells with TNF-α, LPS, and interferon gamma
(IFN-γ) may lead to synergistic super induction of the chemo-
kine CX3CL1 in endothelial cells [14].
TNF-α induces the expression of CX3CL1 and CX3CR1
in a time-dependent manner through at least two signaling
pathways that converge at the point of IKK activation [18,
36]. The IKK complex is the core element of the NF-κB cas-
cade. The trimeric structure of TNF-α corresponds to the re-
spective trimerization of the TNFR1. After ligand binding to
TNFR1, several signaling proteins are recruited to the cyto-
plasmic domain of TNFR1, including the adapter protein
TRADD (TNFR1-associated death domain). Binding of
TRADD and FADD (fas-associated death domain) to TNFR1
leads to the recruitment, oligomerization, and activation of
Caspase 8. Activation of this caspase initiates a proteolytic
cascade and ultimately induces apoptosis. TRADD–TRAF2
(TNF receptor associated factor 2) complex formation is the
other way to induce TNF-α/TNFR1 signaling activity that
leads to activation of NIK, IKK, and NF-κB [37].
TNF-α dependent activation of NF-κB, CX3CL1 produc-
tion, as well as CX3CR1 expression may be significantly in-
fluenced by the changes in SODD (silencer of death domains),
a widely expressed 60 kDa protein associated with the DD of
TNFR1 [38]. SODD is probably involved in a general mech-
anism for preventing spontaneous signaling by DD-
Table 3 TNF-α levels (pg/ml) in the HUVECs cultures measured at the consecutive time points
Time point Group (aspirin dose [mM]
I (1.0) II (2.0) III (3.0) IV (4.0) V (5.0) VI (6.0) VII (0.0; control)
Time after induction by LPS
24 h
Mean 940.1±89 769.0±119 436.3±73 309.5±74 314.5±59 250.4±45 998.9±117
Median 955 748 449 328 303 264 1046
Range 510–1597 400–1412 293–652 202–651 221–543 134–478 679–2005
48 h
Mean 914.7±104 725.4±88 361.2±77 316.8±58 252.2±60 227.6±74 1104.7±106
Median 900 732 377 325 249 238 1046
Range 587–1423 366–1377 187–769 214–601 110–433 125–440 679–1824
72 h
Mean 698.3±103 438.1±104 269.4±58 206.3±61 187.9±44 270.3±76 11021.2±118
Median 703 399 239 201 214 262 1037
Range 345–1098 216–749 173–418 111–429 95–356 154–560 603–1692
144 h
Mean 561.9±92 303.4±90 212.8±45 135.7±40 250.4±57 266.8±61 938.2±92
Median 505 307 194 148 260 231 904
Range 269–978 168–515 96–442 79–261 144–408 100–513 572–1706
Mean±SEM, median (rounded to the nearest whole number), and 95 % confidence interval (95 % CI) are shown
Fig. 2 Cell viability assay of HUVECs exposured to different doses of
aspirin over time (at a given time points)
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Fig. 3 a. Immunohistochemical visualization of the receptor CX3CR1 in
HUVECs culture (the tones of orange-red-brown color; the image cap-
tured through optical microscope was digitally transformed for morpho-
metric purposes); b.Mean final expressions (Ef) of CX3CR1 in HUVECs
cultures exposured to different doses of aspirin (groups I to VI), including
control group VII. The mean initial value of CX3CR1 expression (Ei) was
taken as 100 % for each group. Twenty four visual fields were analysed
within each group I–VII (12 at time point Ei and 12 at Ef, respectively)
Fig. 4 Relationships between aspirin dose and the mean TNF-α levels in the culture media at the consecutive time points
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containing receptors. Overexpression of SODD associated
with the DD of TNFR1 suppresses biological activities of
TNF-α, indicating that SODD plays a role as a negative reg-
ulatory protein for TNF-α/TNFR1 signaling [39]. A recent
report demonstrated that expression of SODD significantly
declined following aspirin exposure [38]. This observation is
consistent with the well-documented pro-apoptotic activity of
aspirin [40].
Our results may indicate that the effect of the decreased
TNF-α that accompanies aspirin treatment may be addition-
ally augmented by the fact that significant modulation of the
TNF-α/TNFR1 signaling pathway causes a decrease in
NF-κB production by HUVECs, which may coexist with
non-changed expression of the TNFR1. The mean level of
CX3CL1 also declines corresponding to the decreased con-
centration of TNF-α (a weaker stimulator of CX3CL1
Fig. 5 a. Immunohistochemical visualization of the receptor TNFR1
(TNFRSF1A) in HUVECs culture (the tones of pink-purple color; the
image captured through optical microscope was digitally transformed
for morphometric purposes); b. Mean final expressions (Ef) of TNFR
SF1A in HUVECs cultures exposured to different doses of aspirin
(groups I to VI), including control group VII. The mean initial value of
TNFRSF1A expression (Ei) was taken as 100 % for each group. Twenty
four visual fields were analysed within each group I–VII (12 at time point
Ei and 12 at Ef, respectively)
Fig. 6 Relationship between
aspirin dose and the mean NF- B
(NF- B/p65 protein heterodimer)
concentrations in HUVECs cell
lysates. The cultures were
subjected to LPS pretreatment
(1 μg/ml)
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production). In contrast, upregulation of CX3CR1 may be a
logical consequence of autoregulation of this receptor by the
mechanism which efficiently utilizes signaling via
heterotrimeric Gi proteins, PI-3 kinase, PDK1, Akt, NIK,
IKK and NF-κB, independent of SODD expression. Thus, a
significant reduction in the level of NF-κB may induce a neg-
ative autoregulatory loop with an observed increase in the
mean CX3CR1 expression. Further studies are needed to re-
veal the relationship between such overexpression of
CX3CR1 and the reported clinical observation from patients
with indications for thrombolytic therapy that the risk of car-
diovascular thrombotic events increases shortly after discon-
tinuation of acetylsalicylic acid [41–43].
Interpretation of our results pertains only to normoxic pri-
mary HUVECs. To obtain maximum homogeneity of the cul-
tures and optimal reproducibility of the results, endothelial
cell lines should be used in future studies. Realizing that pre-
existing infection, hypoxic conditions and/or the use of cancer
cell cultures in experimental models can produce different
results is also important [44, 45]. The activation of signaling
pathways involved in CX3CL1/CX3CR1 regulation in re-
sponse to oxygen deprivation (e.g., pro-angiogenic) or related
to cancerous mutations have been studied by many re-
searchers. Changes in the cytokine network including
TNF-α and CX3CL1 production and their respective receptor
expression were striking [46, 47].
Moreover, the mean expression of the other receptor be-
longing to the TNF receptor superfamily, TNFR2 has not been
studied here. Confirmed in endothelial cells, the expression
profiles, ligand affinities, cytoplasmic tail structure, and
downstream signaling pathway activation of TNFR2 differ
from that documented for TNFR1 [20]. This receptor deserves
our further attention because it is clearly evident from analyses
of TNFR1 knock-out mice that TNFR2 stimulation alone is
sufficient to activate most of the signaling pathways mediated
via TNFR1 [20].
In conclusion, using aspirin concentrations within the ther-
apeutic range in cultured HUVECs, we observed that the
TNF-α level decreased without significant changes in the
mean TNFR1 expression, and inhibited production of
CX3CL1 was accompanied by up regulation of CX3CR1.
Because LPS-induced expression of CX3CL1 in many endo-
thelial cells involves activation of the transcription factor NF-
kB, the mechanism of the anti-aggregatory action of aspirin
may be secondary to the inhibition of NF-kB, which then
reduces the local concentrations of CX3CL1 [21, 29]. Exis-
tence of an autoregulatory mechanism between CX3CL1 and
CX3CR1 may explain the increased expression of CX3CR1
as the compensatory effect in aspirin-treated HUVECs. Phar-
macological inhibition of the chemokine receptor CX3CR1
should be considered as a preventativemeasure for thrombotic
complications in the early period after discontinuation of as-
pirin therapy.
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